Camurus (Q3 initial take): Europe Slack, Growth in the US, Lower R&D - Redeye

Redeye provides its first take on Camurus’ Q3 report 2025, published this morning. Sales of Buvidal and Brixadi were both lower than we had projected, although Brixadi grew by 25% Q/Q. Buvidal had its second sequential sales decline. Operating costs were lower, resulting in a strong EBIT margin. Overall, the report falls short of our expectations.

Länk till analysen i sin helhet: https://www.redeye.se/research/1136313/camurus-q3-initial-take-europe-slack-growth-in-the-us-lower-rd?utm_source=finwire&utm_medium=RSS